Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia

Figures & data

Table 1. Pneumococcal vaccine coverages according to age strata and time elapsed since vaccination.

	PPVS23 VACCINATED
	Within previous 5 yrs n (%)	>5 yrs ago n (%)	At any time n (%)	PCV13 VACCINATED^1 n (%)
50–54 yrs (n = 385,810)	9,237 (2.4)	4,864 (1.3)	14,101 (3.7)	371 (0.1)
55–59 yrs (n = 340,311)	14,321 (4.2)	6,477 (1.9)	20,798 (6.1)	455 (0.1)
60–64 yrs (n = 295,527)	50,603 (17.1)	9,734 (3.3)	60,337 (20.4)	575 (0.2)
65–69 yrs (n = 282,504)	96,992 (34.3)	48,098 (17.0)	145,090 (51.4)	789 (0.3)
70–74 yrs (n = 229,686)	45,138 (19.7)	112,428 (48.9)	157,566 (68.6)	778 (0.3)
75–79 yrs (n = 179,093)	20,848 (11.6)	115,672 (64.3)	136,520 (76.2)	696 (0.4)
80–84 yrs (n = 166,429)	16,515 (9.9)	115,293 (69.3)	131,808 (79.2)	780 (0.5)
85–89 yrs (n = 101,026)	10,039 (9.9)	71,032 (70.3)	81,071 (80.2)	391 (0.4)
≥90 yrs (n = 53,079)	5,380 (10.1)	36,427 (68.6)	41,807 (78.8)	196 (0.3)
Overall (n = 2,033,465)	26,9073 (13.2)	520,025 (25.6)	789,098 (38.8)	5,031 (0.2)

Note: PPSV23, 23-valent pneumococcal polysaccharide vaccine. PCV13, 13 valent pneumococcal conjugate vaccine.

¹ Vaccination at any time.

Table 2. Pneumococcal vaccine coverages according to risk strata and time elapsed since vaccination.

	PPSV23 VACCINATED
	Within previous 5 yrs n (%)	>5 yrs ago n (%)	At any time n (%)	PCV13 VACCINATED^1 n (%)
High risk stratum
50–64 yrs (n = 49,289)	7,368 (14.2)	2,864 (5.5)	10232 (19.7)	752 (1.4)
≥65 yrs (n = 124,319)	23,001 (18.4)	71,252 (57.2)	94,253 (75.6)	1,366 (1.1)
All (n = 176,600)	30,369 (17.2)	74,116 (42.0)	104,485 (59.2)	2,118 (1.2)
Medium risk stratum
50–64 yrs (n = 376,448)	46,666 (12.5)	14,886 (4.0)	61,552 (16.4)	444 (0.1)
≥65 yrs (n = 429,403)	87,488 (20.4)	239,350 (55.8)	326,838 (76.2)	1,689 (0.4)
All (n = 803,710)	134,154 (16.7)	254,236 (31.6)	388,390 (48.3)	2,133 (0.3)
Low risk stratum
50–64 yrs (n = 595,911)	20,127 (3.4)	3,325 (0.6)	23,452 (3.9)	205 (<0 .1)
≥65 yrs (n = 458,095)	84,423 (18.4)	188,348 (41.1)	272,771 (59.6)	575 (0.1)
All (n = 1,053,155)	104,550 (9.9)	191,673 (18.2)	296,223 (28.1)	780 (0.1)
Overall
50–64 yrs (n = 1,021,648)	74,161 (7.3)	21,075 (2.1)	95,236 (9.3)	1,401 (0.1)
≥65 yrs (n = 1,011,817)	194,912 (19.3)	498,950 (49.3)	693,862 (68.6)	3,630 (0.4)
All (n = 2,033,465)	269,073 (13.2)	520,025 (25.6)	789,098 (38.8)	5,031 (0.2)

Note: PPSV23, 23-valent pneumococcal polysaccharide vaccine. PCV13, 13 valent pneumococcal conjugate vaccine.

¹ Vaccination at any time.

Table 3. Unadjusted odds ratios for pneumococcal vaccination (PPSV23, PCV13, any vaccine) according to distinct study covariables.

	PPVS23 VACCINATION^1			PCV13 VACCINATION^1			ANY VACCINE PCV13 or PPSV23^1
	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
Age
50–59 yrs (ref)	1.00	—	—	1.00	—	—	1.00	—	—
60–69 yrs	10.92	(10.79-11.05)	<0.001	2.08	(1.91–2.27)	<0.001	10.82	(10.69-10.95)	<0.001
70–79 yrs	50.78	(50.14–51.44)	<0.001	3.18	(2.92–3.46)	<0.001	50.29	(49.65–50.93)	<0.001
≥80 yrs	76.61	(75.56–77.67)	<0.001	3.76	(3.45–4.10)	<0.001	75.87	(74.83–76.91)	<0.001
Sex
male (ref)	1.00	—	—	1.00	—	—	1.00	—	—
female	1.11	(1.10–1.12)	<0.001	0.70	(0.66–0.74)	<0.001	1.11	(1.10–1.12)	<0.001
Residential area
urban (ref)	1.00	—	—	1.00	—	—	1.00	—	—
rural	1.09	(1.08–1.10)	<0.001	1.96	(1.84–2.08)	<0.001	1.09	(1.08–1.10)	<0.001
Risk strata^2
Low risk(ref)	1.00	—	—	1.00	—	—	1.00	—	—
Medium risk	2.39	(2.38–2.40)	<0.001	3.59	(3.31–3.90)	<0.001	2.39	(2.38–2.41)	<0.001
High risk	3.70	(2.66–3.74)	<0.001	16.38	(15.08–17.78)	<0.001	3.74	(3.70–3.77)	<0.001

Note: PPSV23, 23-valent pneumococcal polysaccharide vaccine. PCV13, 13 valent pneumococcal conjugate vaccine. OR, Odds ratio. CI, Confidence interval.

¹ Vaccination at any time.

² Risk strata definition: high risk is immunocompromised, medium risk is immunocompetent with some risk factors and low risk is immunocompetent without risk factors.

Table 4. Adjusted odds ratios for pneumococcal vaccination (PPSV23, PCV13, any vaccine) according to distinct study covariables.

	PPVS23 VACCINATION^1			PCV13 VACCINATION^1			ANY VACCINE PCV13 or PPSV23^1
	AOR	95% CI	p	AOR	95% CI	p	AOR	95% CI	p
Age
50–59 yrs (ref)	1.00	—	—	1.00	—	—	1.00	—	—
60–69 yrs	11.29	(11.15–11.43)	<0.001	1.78	(1.63–1.95)	<0.001	11.19	(11.05–11.33)	<0.001
70–79 yrs	51.96	(51.27–52.65)	<0.001	2.20	(2.02–2.41)	<0.001	51.44	(50.76–52.11)	<0.001
≥80 yrs	75.23	(74.16–76.31)	<0.001	2.24	(2.05–2.46)	<0.001	74.44	(73.38–75.51)	<0.001
Sex
male (ref)	1.00	—	—	1.00	—	—	1.00	—	—
female	1.02	(1.01–1.03)	<0.001	0.80	(0.76–0.85)	<0.001	1.02	(1.01–1.03)	<0.001
Residential area
urban (ref)	1.00	—	—	1.00	—	—	1.00	—	—
rural	1.12	(1.11–1.13)	<0.001	1.97	(1.85–2.09)	<0.001	1.12	(1.11–1.14)	<0.001
Risk strata^2
Low risk (ref)	1.00	—	—	1.00	—	—	1.00	—	—
Medium risk	2.59	(2.57–2.61)	<0.001	3.32	(3.05–3.62)	<0.001	2.59	(2.57–2.61)	<0.001
High risk	2.39	(2.36–2.42)	<0.001	13.59	(12.47–14.82)	<0.001	2.42	(2.39–2.46)	<0.001

Note: PPSV23, 23-valent pneumococcal polysaccharide vaccine. PCV13, 13 valent pneumococcal conjugate vaccine. AOR, multivariable adjusted odds ratio. CI, Confidence interval.

¹ Vaccination at any time.

² Risk strata definition: High risk is immunocompromised, medium risk is immunocompetent with some risk factors and low risk is immunocompetent without risk factors.